HomeAI · summaries
Storia in 4 fonti
Arrowhead’s gene silencer competitive with Ionis’ in triglyceride disease
Arrowhead's Redemplo cut triglycerides 79%-81% in two Phase 3 trials for sHTG, boosting the company's shares by about 25%.
Confronto fonti
4 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
Arrowhead hits ‘best-case scenario’ with latest results for fat-lowering drug
To analysts, the drug’s apparent safety and effects on both triglyceride levels and pancreatitis cases should make it competitive with a rival Ionis therapy.
- ·
fiercepharma.com
Look out Ionis, here comes Arrowhead with promising hypertriglyceridemia data
Less than a month after Ionis Pharmaceuticals scored an FDA expansion for Tryngolza to become t | Less than a month after Ionis scored an FDA expansion for Tryngolza to become the…
